# Rivus Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rivus-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Charlottesville, US
- Website: www.rivuspharma.com
- Total disclosed funding: $167M
- Latest round: Series B (Sep 22, 2022)
- Investors on record: 6

## About

Founded in 2019 and based in Virginia, US, Rivus Pharmaceuticals, Inc. operates as a biopharmaceutical company for cardio-metabolic health. In September 2022, Rivus Pharmaceuticals, Inc. raised USD 132 million in series B funding led by new investor RA Capital with participation from other new investors BB Biotech Ventures and Bain Capital Life Sciences. Returning investors Longitude Capital, Medicxi Ventures, and RxCapital also participated in the round.

Rivus Pharmaceuticals, Inc. provides a small molecule therapy, HU6, which is a controlled metabolic accelerator (CMA) that addresses the underlying cause of cardio-metabolic disease by harnessing the body's natural processes to improve cellular metabolism.

The company will use the series B funding to further support the clinical advancement of HU6 as a therapy for obesity and cardio-metabolic disorders.

## Funding rounds

- Series B, Sep 22, 2022, $132M — Longitude Capital, RA Capital Management, Medicxi, Bain Capital Life Sciences, Pureos Bioventures, RxCapital
- Series A, Jul 20, 2021, $35M — Longitude Capital, Medicxi, RxCapital

## Investors

- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A, Series B
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series A, Series B
- RxCapital (https://capitalatlas.ai/funds/rxcapital) — Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Bain Capital Life Sciences — Series B
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Series B